News
Turn Therapeutics
TTRX · NASDAQ
$10.47−$0.27 (−2.51%)TodayMarket closed ·
Prev close $10.74
Latest news
- Press releaseBusiness Wire
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
- Press releaseBusiness Wire
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
- Press releaseGlobe Newswire
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
- Press releaseBusiness Wire
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
- Press releaseBusiness Wire
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
- Press releaseBusiness Wire
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
- NewsVandana Singh
Why Is Turn Therapeutics Stock Trading Higher Today?
- News
Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis
- Press releaseBusiness Wire
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
- Press releaseBusiness Wire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
- Press releaseBusiness Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
- Press releaseBusiness Wire
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
- Press releaseBusiness Wire
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
- Press releaseBusiness Wire
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
- Press releaseBusiness Wire
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- News
Turn Therapeutics Q4 EPS $0.01
- Press releaseBusiness Wire
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
- Press releaseBusiness Wire
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
- Press releaseBusiness Wire
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
- Press releaseBusiness Wire
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
- Press releaseBusiness Wire
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
- Press releaseGlobe Newswire
Turn Therapeutics' GX-03 Technology Named as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine
- NewsAvi Kapoor
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings
- NewsAvi Kapoor
US Stocks Mixed; Nasdaq Falls Over 50 Points
- NewsRishabh Mishra
Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED)
- NewsAvi Kapoor
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
PepsiCo, Delta Air Lines And 3 Stocks To Watch Heading Into Thursday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.